Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
AU2012308501 A1 2014-03-13 [AU2012308501]AU2012308501 A2 2014-04-17 [AU2012308501] / 2014-03-132014-04-17
申请号/申请日
2012AU-0308501 / 2012-09-13
发明人
GOJON-ZORRILLA GABRIEL;GOJON-ROMANILLOS GABRIEL;LEFER DAVID J;
申请人
EMORY UNIVERSITY;NUEVAS ALTERNATIVAS NATURALES;
主分类号
IPC分类号
A01N-031/00
摘要
(AU2012308501) The present invention features sulfur-rich compositions and preparations thereof that are safe and effective as hydrogen sulfide prodrugs of high bioavailability.  The invention also includes methods of treating pathological conditions associated with oxidative stress using sulfur-rich compositions.  The invention further includes sulfur-rich compositions as antidotes and medical food for preserving and promoting general health.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2011US-61534585 2011-09-14 2012WO-US55205 2012-09-13
主权利要求
(AU2012308501) 1. A method of treating a condition associated with oxidative stress in a subject in need thereof by administering an effective amount of a composition comprising 90-99.9% (w/w) elemental alpha sulfur and 0.01-10% (w/w) highly polar components, and optionally comprising one or more pharmaceutically acceptable excipients. 2. The method of claim 1, wherein said composition comprises about 99% (w/w) zerovalent sulfur and about 1% (w/w) highly polar components, wherein said highly polar components are selected from sodium sulfate, sodium polythionates, and sodium thiosulfate. 3. The method of claim 1, wherein said highly polar components are selected from the group consisting of: sodium polythionate, potassium polythionate, ammonium polythionate, calcium polythionate, sodium thiosulfate, potassium thiosulfate, ammonium thiosulfate, calcium thiosulfate, sodium sulfate, potassium sulfate, ammonium sulfate, sodium bisulfite, potassium bisulfite, ammonium bisulfite, calcium bisulfite, sodium chloride, potassium chloride, ammonium chloride, calcium chloride, sodium acetate, sodium palmitate, potassium palmitate, and ammonium laurate. 4. A method of treating a condition associated with oxidative stress in a subject in need thereof by administering an effective amount of a composition comprising an elemental alpha sulfur and one or more highly polar components in a ratio from about 10 to about 150 parts elemental alpha sulfur to 1 part highly polar components (w/w) for enteral, topical, or parenteral administration. 5. The method of claim 4, wherein said composition is formulated for enteral administration and said elemental alpha sulfur and said highly polar components are present together in an amount of 400 mg. 6. The method of claim 5, wherein said composition is a capsule. 7. The method of claim 2, wherein said composition is formulated for topical administration, and said composition comprises 1-20% zerovalent sulfur content. 8. The method of claim 7, wherein said composition is a cream. 9. The method of claim 8, wherein said cream comprises (i) 5-20% zerovalent sulfur content and (ii) polyethylene glycol or petroleum jelly. 10. The method of claim 9, wherein said cream comprises 5-15% zerovalent sulfur content. 11. The method of claim 4, further comprising a third agent. 12. The method of claim 11, wherein said third agent is a cardiovascular disease drug, an antiinflammatory drug, an anti-neurodegenerative drug, or an anticancer/anti-proliferative drug. 13. The method of claim 11, wherein said elemental alpha sulfur, said highly polar components, and said third agent are present in an effective amount to treat a condition associated with oxidative stress. 14. The method of claim 4, wherein said condition associated with oxidative stress is selected from the group consisting of: schizophrenia, bipolar disorder, fragile X syndrome, sickle cell disease, chronic fatigue syndrome, osteoarthritis cataract, macular degeneration, toxic hepatitis, viral hepatitis, cirrhosis, chronic hepatitis, oxidative stress from dialysis, renal toxicity, kidney failure, ulcerative colitis, bacterial infection, viral infections, such as HIV and AIDS, herpes, ear infection, upper respiratory tract diseases, hypertension, balding and hair loss, male infertility, over-training syndrome related to athletic performance, athlete's foot, psoriases, eczema, scleroderma, atopic dermatitis, polymyositis, rosacea, dermatitis herpetiformis, other neurodegenerative diseases, other inflammatory disease, and a cancer. 15. The method of claim 14, wherein said condition associated with oxidative stress is a cardiovascular disease. 16. The method of claim 15, wherein said cardiovascular disease is selected from the group consisting of: arteriosclerosis, coronary heart disease, ischemia, endothelium dysfunction, in particular those dysfunctions affecting blood vessel elasticity, restenosis, thrombosis, angina, high blood pressure, cardiomyopathy, hypertensive heart disease, heart failure, cor pulmonale, cardiac dysrhythmias, endocarditis, inflammatory cardiomegaly, myocarditis, myocardial infarction, valvular heart disease, stroke and cerebrovascular disease, aortic valve stenosis, congestive heart failure, and peripheral arterial disease. 17. A method of increasing hydrogen sulfide levels in a subject having a sulfur nutritional deficiency by administering an effective amount of a composition comprising 90-99.9% (w/w) elemental alpha sulfur and 0.01-10% (w/w) highly polar components, and optionally comprising one or more pharmaceutically acceptable excipients. 18. The method of claim 17, further comprising a third agent. 19. The method of claim 18, wherein said third agent is a dietary supplement. 20. The method of claim 18, wherein said elemental alpha sulfur, said highly polar components, and said third agent are present in an effective amount to promote or maintain general health. 21. A method for assessing the treatment of a cardiovascular disease by administering a composition comprising 90-99.9% (w/w) elemental alpha sulfur and 0.01-10% (w/w) highly polar components, and optionally comprising one or more pharmaceutically acceptable excipients, said method comprising: determining the level of hydrogen sulfide in a sample from said subject, adjusting the dose of said composition in an amount sufficient to treat said cardiovascular disease, wherein an increase in the level of hydrogen sulfide or an improvement in a cardiovascular parameter results in the treatment of said cardiovascular disease. 22. The method of claim 21, wherein said cardiovascular parameter is selected from the group consisting of: end-diastolic volume (EDV), end-systolic volume (ESV), stroke volume, ejection fraction, heart rate, and cardiac output.
法律状态
(AU2012308501) LEGAL DETAILS FOR AU2012308501  Actual or expected expiration date=2016-09-22    Legal state=DEAD    Status=LAPSED     Event publication date=2012-09-13  Event code=AU/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=AU AU2012308501  Application date=2012-09-13  Standardized application number=2012AU-0308501     Event publication date=2014-03-13  Event code=AU/A1  Event indicator=Pos  Event type=Examination events  Open to public inspection  Publication country=AU  Publication number=AU2012308501  Publication stage Code=A1  Publication date=2014-03-13  Standardized publication number=AU2012308501     Event publication date=2014-04-17  Event code=AU/A2  Event indicator=Pos  Event type=Examination events  Amended post open to publ. inspec.  Publication country=AU  Publication number=AU2012308501  Publication stage Code=A2  Publication date=2014-04-17  Standardized publication number=AU2012308501     Event publication date=2014-04-17  Event code=AU/DA3  Event type=Corrections  Amendments made section 104 THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 FEB 2014     Event publication date=2016-09-22  Event code=AU/MK5  Event indicator=Neg  Event type=Event indicating Not In Force  Application lapsed section 142(2)(e) - patent request and compl. specification not accepted
专利类型码
A1A2
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部